Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 153 of 153 entries
Sorted by: Best Match Show Resources per page
Ependymomas overexpress chemoresistance and DNA repair-related proteins.

Oncotarget

Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB.
PMID: 29487694
Oncotarget. 2017 Dec 15;9(8):7822-7831. doi: 10.18632/oncotarget.23288. eCollection 2018 Jan 30.

BACKGROUND: After surgery and radiation, treatment options for ependymoma are few making recurrence a challenging issue. Specifically, the efficacy of chemotherapy at recurrence is limited. We performed molecular profiling on a cohort of ependymoma cases in order to uncover...

Cite
Ferguson SD, Zhou S, Xiu J, et al. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2017;9(8):7822-7831doi: 10.18632/oncotarget.23288.
Ferguson, S. D., Zhou, S., Xiu, J., Hashimoto, Y., Sanai, N., Kim, L., Kesari, S., de Groot, J., Spetzler, D., & Heimberger, A. B. (2018). Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget, 9(8), 7822-7831. https://doi.org/10.18632/oncotarget.23288
Ferguson, Sherise D, et al. "Ependymomas overexpress chemoresistance and DNA repair-related proteins." Oncotarget vol. 9,8 (2018): 7822-7831. doi: https://doi.org/10.18632/oncotarget.23288
Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2017 Dec 15;9(8):7822-7831. doi: 10.18632/oncotarget.23288. eCollection 2018 Jan 30. PMID: 29487694; PMCID: PMC5814261.
Copy Download .nbib Format: NLM
The Behavioral Consequence of Phenylketonuria in Mice Depends on the Genetic Background.

Frontiers in behavioral neuroscience

Bruinenberg VM, van der Goot E, van Vliet D, de Groot MJ, Mazzola PN, Heiner-Fokkema MR, van Faassen M, van Spronsen FJ, van der Zee EA.
PMID: 28066199
Front Behav Neurosci. 2016 Dec 20;10:233. doi: 10.3389/fnbeh.2016.00233. eCollection 2016.

To unravel the role of gene mutations in the healthy and the diseased state, countless studies have tried to link genotype with phenotype. However, over the years, it became clear that the strain of mice can influence these results....

Cite
Bruinenberg VM, van der Goot E, van Vliet D, et al. The Behavioral Consequence of Phenylketonuria in Mice Depends on the Genetic Background. Front Behav Neurosci. 2016;10:233doi: 10.3389/fnbeh.2016.00233.
Bruinenberg, V. M., van der Goot, E., van Vliet, D., de Groot, M. J., Mazzola, P. N., Heiner-Fokkema, M. R., van Faassen, M., van Spronsen, F. J., & van der Zee, E. A. (2016). The Behavioral Consequence of Phenylketonuria in Mice Depends on the Genetic Background. Frontiers in behavioral neuroscience, 10233. https://doi.org/10.3389/fnbeh.2016.00233
Bruinenberg, Vibeke M, et al. "The Behavioral Consequence of Phenylketonuria in Mice Depends on the Genetic Background." Frontiers in behavioral neuroscience vol. 10 (2016): 233. doi: https://doi.org/10.3389/fnbeh.2016.00233
Bruinenberg VM, van der Goot E, van Vliet D, de Groot MJ, Mazzola PN, Heiner-Fokkema MR, van Faassen M, van Spronsen FJ, van der Zee EA. The Behavioral Consequence of Phenylketonuria in Mice Depends on the Genetic Background. Front Behav Neurosci. 2016 Dec 20;10:233. doi: 10.3389/fnbeh.2016.00233. eCollection 2016. PMID: 28066199; PMCID: PMC5167755.
Copy Download .nbib Format: NLM
Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.

Cancer cell

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB.
PMID: 31085179
Cancer Cell. 2019 May 13;35(5):816. doi: 10.1016/j.ccell.2019.04.011.

No abstract available.

Cite
Ma J, Benitez JA, Li J, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 2019;35(5):816doi: 10.1016/j.ccell.2019.04.011.
Ma, J., Benitez, J. A., Li, J., Miki, S., Ponte de Albuquerque, C., Galatro, T., Orellana, L., Zanca, C., Reed, R., Boyer, A., Koga, T., Varki, N. M., Fenton, T. R., Nagahashi Marie, S. K., Lindahl, E., Gahman, T. C., Shiau, A. K., Zhou, H., DeGroot, J., Sulman, E. P., Cavenee, W. K., Kolodner, R. D., Chen, C. C., & Furnari, F. B. (2019). Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer cell, 35(5), 816. https://doi.org/10.1016/j.ccell.2019.04.011
Ma, Jianhui, et al. "Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair." Cancer cell vol. 35,5 (2019): 816. doi: https://doi.org/10.1016/j.ccell.2019.04.011
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 2019 May 13;35(5):816. doi: 10.1016/j.ccell.2019.04.011. PMID: 31085179; PMCID: PMC8717880.
Copy Download .nbib Format: NLM
Seasonal Trends for Environmental Illness Incidence in the U.S. Army.

Military medicine

DeGroot DW, Rappole CA, McHenry P, Englert RM.
PMID: 33605408
Mil Med. 2021 Feb 19; doi: 10.1093/milmed/usab072. Epub 2021 Feb 19.

INTRODUCTION: The incidence of and risk factors for exertional heat illness (EHI) and cold weather injury (CWI) in the U.S. Army have been well documented. The "heat season", when the risk of EHI is highest and application of risk...

Cite
DeGroot DW, Rappole CA, McHenry P, et al. Seasonal Trends for Environmental Illness Incidence in the U.S. Army. Mil Med. 2021;doi: 10.1093/milmed/usab072.
DeGroot, D. W., Rappole, C. A., McHenry, P., & Englert, R. M. (2021). Seasonal Trends for Environmental Illness Incidence in the U.S. Army. Military medicine, . https://doi.org/10.1093/milmed/usab072
DeGroot, David W, et al. "Seasonal Trends for Environmental Illness Incidence in the U.S. Army." Military medicine vol. (2021). doi: https://doi.org/10.1093/milmed/usab072
DeGroot DW, Rappole CA, McHenry P, Englert RM. Seasonal Trends for Environmental Illness Incidence in the U.S. Army. Mil Med. 2021 Feb 19; doi: 10.1093/milmed/usab072. Epub 2021 Feb 19. PMID: 33605408.
Copy Download .nbib Format: NLM
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.

Nature cancer

Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA.
PMID: 33521652
Nat Cancer. 2020 Apr;1:423-436. doi: 10.1038/s43018-019-0020-z. Epub 2020 Feb 17.

The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mechanisms underlying this evolution remain obscure due to scarcity of post-relapse tissue samples. We generated circulating tumor cell (CTC)-derived xenografts (CDXs) from...

Cite
Stewart CA, Gay CM, Xi Y, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423-436doi: 10.1038/s43018-019-0020-z.
Stewart, C. A., Gay, C. M., Xi, Y., Sivajothi, S., Sivakamasundari, V., Fujimoto, J., Bolisetty, M., Hartsfield, P. M., Balasubramaniyan, V., Chalishazar, M. D., Moran, C., Kalhor, N., Stewart, J., Tran, H., Swisher, S. G., Roth, J. A., Zhang, J., de Groot, J., Glisson, B., Oliver, T. G., Heymach, J. V., Wistuba, I., Robson, P., Wang, J., & Byers, L. A. (2020). Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature cancer, 1423-436. https://doi.org/10.1038/s43018-019-0020-z
Stewart, C Allison, et al. "Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer." Nature cancer vol. 1 (2020): 423-436. doi: https://doi.org/10.1038/s43018-019-0020-z
Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 Apr;1:423-436. doi: 10.1038/s43018-019-0020-z. Epub 2020 Feb 17. PMID: 33521652; PMCID: PMC7842382.
Copy Download .nbib Format: NLM
Synthetic .

Journal of the American Chemical Society

Li Z, Unione L, Liu L, Lang Y, de Vries RP, de Groot RJ, Boons GJ.
PMID: 34967208
J Am Chem Soc. 2022 Jan 12;144(1):424-435. doi: 10.1021/jacs.1c10329. Epub 2021 Dec 30.

No abstract available.

Cite
Li Z, Unione L, Liu L, et al. Synthetic . J Am Chem Soc. 2021;144(1):424-435doi: 10.1021/jacs.1c10329.
Li, Z., Unione, L., Liu, L., Lang, Y., de Vries, R. P., de Groot, R. J., & Boons, G. J. (2022). Synthetic . Journal of the American Chemical Society, 144(1), 424-435. https://doi.org/10.1021/jacs.1c10329
Li, Zeshi, et al. "Synthetic ." Journal of the American Chemical Society vol. 144,1 (2022): 424-435. doi: https://doi.org/10.1021/jacs.1c10329
Li Z, Unione L, Liu L, Lang Y, de Vries RP, de Groot RJ, Boons GJ. Synthetic . J Am Chem Soc. 2022 Jan 12;144(1):424-435. doi: 10.1021/jacs.1c10329. Epub 2021 Dec 30. PMID: 34967208.
Copy Download .nbib Format: NLM
Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis.

World journal of diabetes

De Groot J, Wu D, Flynn D, Robertson D, Grant G, Sun J.
PMID: 33594336
World J Diabetes. 2021 Feb 15;12(2):170-197. doi: 10.4239/wjd.v12.i2.170.

BACKGROUND: Telemedicine is defined as the delivery of health services AIM: To evaluate the effects of telemedicine interventions on hemoglobin A1c (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), post-prandial glucose (PPG), fasting plasma...

Cite
De Groot J, Wu D, Flynn D, et al. Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis. World J Diabetes. 2021;12(2):170-197doi: 10.4239/wjd.v12.i2.170.
De Groot, J., Wu, D., Flynn, D., Robertson, D., Grant, G., & Sun, J. (2021). Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis. World journal of diabetes, 12(2), 170-197. https://doi.org/10.4239/wjd.v12.i2.170
De Groot, Julia, et al. "Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis." World journal of diabetes vol. 12,2 (2021): 170-197. doi: https://doi.org/10.4239/wjd.v12.i2.170
De Groot J, Wu D, Flynn D, Robertson D, Grant G, Sun J. Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis. World J Diabetes. 2021 Feb 15;12(2):170-197. doi: 10.4239/wjd.v12.i2.170. PMID: 33594336; PMCID: PMC7839169.
Copy Download .nbib Format: NLM
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA.
PMID: 33199490
Clin Cancer Res. 2021 Feb 15;27(4):1048-1057. doi: 10.1158/1078-0432.CCR-20-2500. Epub 2020 Nov 16.

PURPOSE: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma.PATIENTS AND METHODS: Eighty bevacizumab-naïve patients with recurrent glioblastoma were randomized to pembrolizumab with...

Cite
Nayak L, Molinaro AM, Peters K, et al. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020;27(4):1048-1057doi: 10.1158/1078-0432.CCR-20-2500.
Nayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., Nghiemphu, L., Kaley, T., Colman, H., McCluskey, C., Gaffey, S., Smith, T. R., Cote, D. J., Severgnini, M., Yearley, J. H., Zhao, Q., Blumenschein, W. M., Duda, D. G., Muzikansky, A., Jain, R. K., Wen, P. Y., & Reardon, D. A. (2021). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 1048-1057. https://doi.org/10.1158/1078-0432.CCR-20-2500
Nayak, Lakshmi, et al. "Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,4 (2021): 1048-1057. doi: https://doi.org/10.1158/1078-0432.CCR-20-2500
Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 Feb 15;27(4):1048-1057. doi: 10.1158/1078-0432.CCR-20-2500. Epub 2020 Nov 16. PMID: 33199490; PMCID: PMC8284901.
Copy Download .nbib Format: NLM
Towards collective moral resilience: the potential of communities of practice during the COVID-19 pandemic and beyond.

Journal of medical ethics

Delgado J, Siow S, de Groot J, McLane B, Hedlin M.
PMID: 33762300
J Med Ethics. 2021 Mar 24; doi: 10.1136/medethics-2020-106764. Epub 2021 Mar 24.

This paper proposes communities of practice (CoP) as a process to build moral resilience in healthcare settings. We introduce the starting point of moral distress that arises from ethical challenges when actions of the healthcare professional are constrained. We...

Cite
Delgado J, Siow S, de Groot J, et al. Towards collective moral resilience: the potential of communities of practice during the COVID-19 pandemic and beyond. J Med Ethics. 2021;doi: 10.1136/medethics-2020-106764.
Delgado, J., Siow, S., de Groot, J., McLane, B., & Hedlin, M. (2021). Towards collective moral resilience: the potential of communities of practice during the COVID-19 pandemic and beyond. Journal of medical ethics, . https://doi.org/10.1136/medethics-2020-106764
Delgado, Janet, et al. "Towards collective moral resilience: the potential of communities of practice during the COVID-19 pandemic and beyond." Journal of medical ethics vol. (2021). doi: https://doi.org/10.1136/medethics-2020-106764
Delgado J, Siow S, de Groot J, McLane B, Hedlin M. Towards collective moral resilience: the potential of communities of practice during the COVID-19 pandemic and beyond. J Med Ethics. 2021 Mar 24; doi: 10.1136/medethics-2020-106764. Epub 2021 Mar 24. PMID: 33762300; PMCID: PMC7992383.
Copy Download .nbib Format: NLM
Showing 145 to 153 of 153 entries